TABLE 2.
Longitudinal carriage of putative AREF strains in dogs with pyoderma in longitudinal study B
| Dog identification no. | ST of AREF isolate or resulta for sample from day:
|
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 6 | 8 | 10 | 12 | 14 | 16 | 18 | 20 | 22 | 29 | |
| B1b | − | 192 | + | + | + | + | + | + | + | + | + | + | − | + |
| B2b | − | − | − | − | − | − | − | − | − | − | − | − | − | − |
| B3b | − | − | − | − | − | + | + | − | 78 | + | − | − | + | NR |
| B4c | + | 78 | + | + | + | − | + | − | − | + | NR | + | − | + |
| B5c | 192 | − | − | − | − | − | − | − | + | + | NR | − | − | + |
| B6c | − | NR | - | 19 | + | + | + | + | + | + | + | + | + | + |
| B7c | − | − | − | − | − | − | − | − | − | − | − | − | NR | − |
| B8c | − | − | NR | − | − | − | − | NR | NR | − | − | − | NR | NR |
| B9d | − | 19 | NR | + | + | + | + | + | − | + | − | − | − | + |
| B10d | − | 19 | + | NR | + | − | + | − | − | − | − | NR | − | − |
| B11d | NR | 78 | + | − | − | − | − | − | − | NR | − | NR | − | NR |
| B12d | − | − | NR | − | − | − | 78 | − | − | NR | NR | NR | − | − |
a
Samples from 12 dogs (B1 to B12) with pyoderma being treated with β-lactams were analyzed. Numbers refer to STs of isolates verified as AREF. +, putative AREF isolate, not characterized; −, no growth on Slanetz-Bartley agar with ampicillin; NR, sample not received.
b
Dog was treated daily with amoxicillin-clavulanic acid tablets from day 1 until day 14.
c
Dog was treated daily with cephalexin tablets from day 1 until day 14.
d
Dog was treated by cefovecin injection on day 1.